Nexvet doubles net loss; Oasmia ups its IPO proceeds; Jaguar starts trials of equine ulcer drug;

> Nexvet Biopharma ($NVET) reported that its net loss in its fiscal first quarter nearly doubled year over year to $4 million, due largely to an increase in expenses related to two of its lead experimental compounds, NV-01 and NV-02. Release

> Oasmia Pharmaceutical ($OASM) announced that due to an additional and partial exercise of the overallotment option granted to underwriters of its recent IPO, its aggregate gross proceeds of the offering increased from $9.5 million to $10.4 million. Release

> Jaguar Animal Health ($JAGX) announced it has launched a proof-of-concept study of a new drug derived from the Croton lechleri tree to treat ulcers in horses. Release

> Kindred Biosciences ($KIN) announced that in the third quarter, its net loss widened year over year from $6.1 million to $7.1 million as its R&D expenses grew, and that the company has $83.6 million in cash and equivalents. Release

> Akorn ($AKRX) announced that it has been informed by Nasdaq that its shares are subject to suspension and delisting due to its delinquency in filing financial reports, and that it has requested a hearing to discuss the matter. Filing

> Ralco, a global distributor of livestock health and nutrition products, has announced it will acquire Bakker Consulting, which makes animal and plant nutrition products. Release

> Abaxis ($ABAX) has declared a quarterly cash dividend of $0.11, payable December 17. Release

> Henry Schein ($HSIC) has made a commitment to Mission Rabies to donate products worth more than $60,000 to support a rabies vaccination campaign in Malawi. Release

> A team of American and Chinese researchers has found that the fungus responsible for the deadly bat disease white-nose syndrome widely affects bats in northeast China. Release

> Patterson ($PDCO) Veterinary has partnered with Voyce to distribute a remote monitoring service that veterinarians can use to track key vital signs in dogs, such as resting heart rate, activity and quality of rest. Release

> Regeneus announced that it has secured a "global top-5 animal health company" to commercialize its stem cell product for dogs, CryoShot Canine, and has launched a trial of the product in dogs with arthritis. Release

> The USDA has awarded more than $4.5 million to 49 American veterinarians to help repay their college loans, in return for them agreeing to work in markets where veterinary services are sparse. Release

> H.J. Baker has hired Jerry Foss, formerly of Huvepharma, as director of U.S. sales for its animal health and nutrition division. Release

> Veterinary Specialists of North America announced it has added two New Jersey animal hospitals to its network: Animal Emergency & Referral Associates of Fairfield and Animal Eye Center of New Jersey of Little Falls. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…